Gentronix Ltd.
The cost of drug discovery continues to rise while the output of new NDAs continues t...
BlueScreen HC uses a single cell strain, which permits 8 compounds to be tested acros...
BlueScreen HC is based on the fast, accurate GreenScreen HC genotoxicity assay from ...
In 2008 Gentronix launches a new S9 protocol to extend the application of the GreenS...
Gentronix has launched a new, accurate and fast in vitro mammalian cell genotoxici...
Gentronix was founded in 1999 as a spin-out from The University of Manchester to commercialise patented new technology for the early identification of genotoxic carcinogens. This technology is now available in a kit format, known as GreenScreen HC, for the early genotoxicity screening of new drug compounds.
Developed in a simple microplate format requiring less than 1mg of compound, the assay is easily automated using standard laboratory equipment. Published results and trial data demonstrate a unique combination of exceptionally high sensitivity and specificity, making GreenScreen HC the first in vitro mammalian cell assay truly suitable for early candidate screening.